A Phase 2 trial of INT-767 in nonalcoholic steatohepatitis (NASH) patients with fibrosis

Trial Profile

A Phase 2 trial of INT-767 in nonalcoholic steatohepatitis (NASH) patients with fibrosis

Planning
Phase of Trial: Phase II

Latest Information Update: 04 May 2017

At a glance

  • Drugs INT 767 (Primary)
  • Indications Fibrosis; Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 May 2017 According to an Intercept Pharmaceuticals media release, company plans to initiate this trial in second half of 2017.
    • 01 Mar 2017 New trial record
    • 23 Feb 2017 According to an Intercept Pharmaceuticals media release, company has planned initiation of this trial in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top